title: [Wilson's disease with severe neurological manifestations: response to trientine plus zinc therapy].
abstract: In patients with Wilson's disease and neurological manifestations, treatment with D-penicillamine can cause worsening of neurological symptoms, usually in the first few weeks of treatment. Because the neurological damage can be severe and irreversible, the use of D-penicillamine is controversial, and several authors believe that it should be avoided. Studies of the use of ammonium tetrathiomolybdate as an alternative chelating agent for the initial treatment of neurologic Wilson's disease are still in the experimental phase. Published experience on the simultaneous use of trientine, another chelating agent, and zinc, which blocks intestinal absorption of copper, is promising but limited. We present the case of a 17 year-old boy with severe neurologic Wilson's disease that had first presented six years previously. The patient showed a complete recovery after six months of treatment with a combination of trientine and zinc acetate.
authors.affiliation: Servicio de Medicina Interna, Hospital de Sagunto, Sagunto, Valencia, Spain.
authors.forename: B
authors.initials: B
authors.lastname: Serra
authors.forename: J
authors.initials: J
authors.lastname: Primo
authors.forename: M
authors.initials: M
authors.lastname: García
authors.forename: I
authors.initials: I
authors.lastname: Amorós
authors.forename: M
authors.initials: M
authors.lastname: Aragó
authors.forename: C
authors.initials: C
authors.lastname: Merino
mesh_terms: D000293:Adolescent; D002614:Chelating Agents / Q000627:therapeutic use*; D006527:Hepatolenticular Degeneration / Q000150:complications*; D006801:Humans; D008297:Male; D009422:Nervous System Diseases / Q000188:drug therapy* / Q000209:etiology; D012720:Severity of Illness Index; D014266:Trientine / Q000627:therapeutic use*; D019345:Zinc Acetate / Q000627:therapeutic use*
chemical_list: D002614:Chelating Agents; D019345:Zinc Acetate; D014266:Trientine